Trial reportBone marrow transplantation2010
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT.
Trial report in Bone marrow transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Pre-emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer.The Cochrane database of systematic reviews · 2022Pooled it
- Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people.The Cochrane database of systematic reviews · 2019Pooled it
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.BMC infectious diseases · 2015Pooled it
- Pooled it
- Exhaled Breath Condensate Surveillance forOpen forum infectious diseases · 2024Article
- Blood Aspergillus PCR: The Good, the Bad, and the Ugly.Journal of fungi (Basel, Switzerland) · 2020Review
- Review
- Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.Bone marrow transplantation · 2015Article
- Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).Turkish journal of haematology : official journal of Turkish Society of Haematology · 2015Review
- Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how.Current oncology reports · 2013Review
- Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections.Current fungal infection reports · 2013Article
- Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome.Scientifica · 2013Review
- Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients.International journal of hematology · 2012Article
- Standardization of Aspergillus PCR diagnosis.Bone marrow transplantation · 2012Article
- Assessing responses to treatment of opportunistic mycoses and salvage strategies.Current infectious disease reports · 2011Article
- Silent and prolonged Aspergillus DNAemia in oncohematological patients receiving antifungal prophylaxis: a new phenomenon with clinical implications.Bone marrow transplantation · 2011Article
- Standardization of Aspergillus PCR is needed.Bone marrow transplantation · 2011Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal infections (IFIs) are major complications after allogeneic hematopoietic SCT (HSCT). PCR-based assays able to detect fungal DNA have been reported to precede clinical diagnosis of IFI. We performed a prospective study to evaluate a PCR-based pre-emptive approach. Ninety-nine patients undergoing reduced-intensity conditioning (RIC) HSCT were followed with fungal PCR during the first 100 days post transplantation. Patients who tested positive were randomized to receive liposomal amphotericin B, or to no intervention. After day 100, PCR tests were performed only on clinical suspicion of IFI. A single positive PCR test was not associated with IFI, irrespective of treatment. After day 100, PCR tests for Aspergillus did not contribute to diagnosis of invasive aspergillosis (IA). The cumulative incidence rates of proven or probable IA during the first year after transplantation were 9%. GVHD grades II-IV (P=0.0014), CMV-seronegative recipient with CMV-seropositive donor (P0.001), and conditioning with alemtuzumab (P=0.014) were significant risk factors for developing IA in a multivariate model. In this study, PCR on peripheral blood was a poor indicator of IFI early after RIC HSCT. Aspergillus PCR tests performed on clinical suspicion after day 100 were insufficiently sensitive to be diagnostically useful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.